Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Cisplatin in Advanced Cervical Cancer
NCT00101192Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Sep 2004
- Primary completion
- Jul 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoints: Objective Tumor Response up to 6 months and Nature and Degree of Toxicity. Started Sep 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00101192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101192.